Previous Article | Next Article 
Molecular and Cellular Biology, June 2000, p. 4328-4339, Vol. 20, No. 12
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Novel Mechanism of Steroid Action in Skin through
Glucocorticoid Receptor Monomers
Nadezda
Radoja,1,2
Mayumi
Komine,1,3
Sang H.
Jho,1
Miroslav
Blumenberg,1,4 and
Marjana
Tomic-Canic1,2,*
The Ronald O. Perelman Department of
Dermatology1 and
Biochemistry,4 New York University
School of Medicine, New York, New York, 10016; Department of
Dermatology, Faculty of Medicine, University of Tokyo, Tokyo,
Japan3; and Institute "Vinca,"
Belgrade, Yugoslavia2
Received 16 August 1999/Returned for modification 1 October
1999/Accepted 20 March 2000
 |
ABSTRACT |
Glucocorticoids (GCs), important regulators of epidermal growth,
differentiation, and homeostasis, are used extensively in the treatment
of skin diseases. Using keratin gene expression as a paradigm of
epidermal physiology and pathology, we have developed a model system to
study the molecular mechanism of GCs action in skin. Here we describe a
novel mechanism of suppression of transcription by the glucocorticoid
receptor (GR) that represents an example of customizing a device for
transcriptional regulation to target a specific group of genes within
the target tissue, in our case, epidermis. We have shown that GCs
repress the expression of the basal-cell-specific keratins K5 and K14
and disease-associated keratins K6, K16, and K17 but not the
differentiation-specific keratins K3 and K10 or the simple
epithelium-specific keratins K8, K18, and K19. We have identified the
negative recognition elements (nGREs) in all five regulated keratin
gene promoters. Detailed footprinting revealed that the function of
nGREs is to instruct the GR to bind as four monomers. Furthermore,
using cotransfection and antisense technology we have found that,
unlike SRC-1 and GRIP-1, which are not involved in the GR complex that
suppresses keratin genes, histone acetyltransferase and CBP are. In
addition, we have found that GR, independently from GREs, blocks the
induction of keratin gene expression by AP1. We conclude that GR
suppresses keratin gene expression through two independent mechanisms:
directly, through interactions of keratin nGREs with four GR monomers,
as well as indirectly, by blocking the AP1 induction of keratin gene expression.
 |
INTRODUCTION |
Glucocorticoids (GCs) mediate their
effect through nuclear receptors, transcription factors that, depending
on the presence or absence of the ligand, regulate gene expression. The
glucocorticoid receptor (GR) is stored in the cytoplasm in its inactive
form, bound to the heat shock protein Hsp90 (49). Ligand
binding causes activation of the receptor, release from Hsp90,
and its translocation to the nucleus. Activated GR binds specific
DNA sequences in target genes, designated glucocorticoid response
elements (GREs), and either induces or suppresses gene transcription
(1, 2, 6, 57).
Recent studies have identified a group of proteins that interact with
nuclear receptors called coregulators. Depending on their effect on
transcription, the coregulators are designated as coactivators or
corepressors (24, 56). The liganded receptor binds to the
response elements and recruits coactivators (such as SRC-1, GRIP-1,
NCoA, or TIF-2) that interact with cointegrators such as p-CIP and
CBP/p300 (7, 15, 22, 28, 45, 67). The cointegrators bind
histone acetyltransferase (HAT), which leads to the induction of
transcription (39, 47, 73). In addition, CBP/p300 itself is
a histone acetylase that can induce transcription without further
interaction with HAT (42, 67). Although the role of the
coregulators in transcriptional regulation by NRs, including GR, is a
rapidly developing area of research, very little is known about the
role of coregulators in active repression, i.e., in the suppression of
transcription by liganded receptors.
Skin is a major target tissue for GC action. Corticosteroids, analogs
of the glucocorticoid hormone, are the most commonly used therapeutic
agents in dermatology (5, 58, 70). They have been used as
immunosuppressive agents for T-cell or cytokine-mediated tissue damage.
They suppress ICAM-1, interleukin-1 (IL-1), IL-2, IL-6,
granulocyte-macrophage colony-stimulating factor, tumor necrosis factor
alpha, and gamma interferon (IFN-
), which are all components of the
immune response (8, 29). In addition, GCs act as growth
inhibitory agents and affect cell-cell interactions (55).
However, very little is known about the molecular mechanisms of GC
action in epidermis. Therefore, to begin to understand such a complex
subject, we have developed a model system in which we use keratins, a
family of differentially expressed epidermal genes, as reporters of GC
action in epidermis. We have focused on the regulation of the keratin
gene expression by GCs because this large family of epithelium-specific
genes has a very precise expression pattern reflecting the
physiological and pathological states of the epithelial cells (4,
17).
Initially, we focused on the following questions: what are the effects
of GCs on epidermal gene expression, how are they mediated, and most
importantly, how do such general and potent transcription factors
specifically target and regulate gene expression in this tissue?
Interestingly, we found that GCs suppress the expression of a subset of
the keratin genes K5-K14, K6-K16, and K17, whose expression is
altered in cutaneous diseases (64). GCs regulate these genes
through two different and independent mechanisms. First, GCs directly
suppress transcription through a novel mechanism that involves
binding of four monomers of the GR to the keratin GREs. This mechanism
substantially differs from all those previously described because it
uses monomers rather than dimers of GR, it involves different
coregulators, and it uses HAT to suppress transcription rather than
induce it. The second, independent mechanism of GC function is by
blocking the AP1-mediated induction of keratin gene expression. AP1 is
commonly active in the proliferative and inflammatory processes for
which GCs are usually prescribed.
The effect of GCs on keratin gene expression reflects directly their
specific action in epidermal physiology because GCs target only the
keratin genes expressed during the inflammatory response and
wound-healing process. The mechanism through which the regulation occurs is a novel one that represents an exciting example of tissue specificity in hormone action.
 |
MATERIALS AND METHODS |
Plasmids, their growth, and their purification.
Plasmids
pK14CAT, pK5CAT, pK6CAT, pK16CAT, pK3CAT, pK10CAT, pK17CAT, pK19CAT,
pK14M1113, K17M1, K5M1, and pRSVZ have been described previously
(27, 62). The plasmids pK8 and pK18 were gifts from R. Oshima (46), pK13 was a gift from J. Schweizer (61), plasmids containing human GR nuclear receptor and
GRE-CAT were gifts from P. Chambon (18), TK-CAT plasmid was
a gift from H. H. Samuels (14), plasmid containing NCoR
was a gift from C. K. Glass (21), plasmid containing
SRC-1 was a gift from B. O'Malley (44), CBP was from
R. H. Goodman (30), and plasmid containing GRIP1 was a
gift from M. Stallcup (23). Plasmids were grown in JM101
E. coli host to saturation density in Luria-Bertani medium.
DNA was extracted and purified using the Mega Prep Kit from Promega.
Cloning and mutagenesis.
We have used a previously
described method (63) to mutagenize the primary GRE
site in the K17 promoter and create K17GREM1. The primers used
for the PCRs were K17outF (5'-GGGTCTAGACAACCCATTTCCCCACCA), K17insR (5'-TTTACTAGTTTTTATTCCCCTGGGCTTTCATCACCA),
K17insF (5'-TTTACTAGTGAGCAAGCCTGTTGTAATCGC), and
K17outR (5'-GGGAAGCTTCATCATGGTGGCGGCGGC); K17GREM4 was
previously described as K17M1 by Radoja et al. (51). K5M1
and K14M1 were also previously described (51, 65).
KRETKCAT contains the acidic signature sequence motif cloned into the
TKCAT (gift from H. H. Samuels). The primers used for the PCR were
KREf (5'-TTTTAAGCTTGCCCCCCAGCCACCTG) and KREr
(5'-TTTTCTCGACGCTTTGCTCCTCTGT).
The insert was introduced using
HindIII and
SalI restriction sites. Positive clones in all cloning
procedures were identified
by restriction digestion and subsequently by
sequencing.
Cell growth.
HeLa cells were maintained in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% calf serum at 37°C in a
5% CO2 atmosphere in medium containing penicillin and
streptomycin as described earlier (62). The day before
transfection cells were plated onto 60-mm dishes. At 4 h before
transfection the medium was changed to phenol-red-free DMEM
supplemented with charcoal-pretreated 10% calf serum depleted of
steroids as described elsewhere (62).
Normal human foreskin epidermal keratinocytes were a generous gift from
M. Simon. The cultures were initiated using 3T3 feeder
layers as
described earlier (
52) and then frozen in liquid
N
2 until used. Once thawed, the keratinocytes were grown
without
feeder cells in defined serum-free keratinocyte medium
supplemented
with epidermal growth factor and bovine pituitary extract
(Keratinocyte-SFM;
GIBCO). Cells were expanded through two 1:4 passages
before transfection
and transfected at 100%
confluency.
Transfection using
Ca3(PO4)2.
We have generally
followed the published procedure for cells that were at 80% confluence
(25). At the time of transfection 3 µg of the CAT plasmid,
1 µg of the nuclear receptor expression vector plasmid, 1 µg of the
pRSVZ reference plasmid, and a sufficient amount of carrier were added
into each dish to bring the total to 10 µg of DNA. After transfection
cells were incubated in phenol-red-free DMEM supplemented with
charcoal-pretreated 10% calf serum depleted of steroids in the
presence or absence of 0.1 or 1 µM dexamethasone (DEX; Sigma) in
ethanol. Then, 10 nM trichostatin A (TSA) in ethanol (Wako Bioproducts)
was used where indicated. The cells were harvested at 48 h after
transfection by scraping them into 5 ml of phosphate-buffered saline
(PBS), washed once more in PBS, and resuspended in 150 µl of 0.25 M
Tris buffer at pH 7.8. All transfections were performed in duplicate
plates, and each transfection experiment was repeated two to five
times. The CAT and
-galactosidase assays were performed as described
earlier (25, 62).
Transfection using polybrene with DMSO shock.
We used
transfections with polybrene and dimethyl sulfoxide (DMSO) to transfect
the DNA into the 100% confluent keratinocytes as previously described
(25). On the day of transfection cells were washed and
incubated in the basal medium without epidermal growth factor EGF or
bovine pituitary extract. Each transfection contained 10 to 15 µg of
keratin-CAT construct and 3 µg of RSVZ construct per dish. The cells
were then incubated with or without 0.1 or 1 µM DEX (Sigma) dissolved
in ethanol. At 36 to 48 h after transfection cells were washed
twice with PBS and then harvested by scraping. The cell disruption by
repeated freeze-thaw cycles, as well as the CAT and
-galactosidase
assays, has also been described (25, 62).
Use of antisense oligonucleotides.
We used oligonucleotides
with the sequences CATCTTGCTCGCCTCCCCCGC for human HDAC1
mRNA, ATTTCCGAGCTACGATCACCCGC for human HAT 1 (HAT1)
mRNA (69) and, as a control, TGGATCATCTTCTGCCATTCT for NF-
B mRNAs. They were synthesized as phosphorothioates
to prolong their half-lives in the cells. These sequences were designed to bind the initiation codon and the sequences immediately upstream, sites that commonly confer the most efficient antisense blocking. The
cells were incubated in 1% delipidized medium from the beginning of
transfection. The antisense DNAs were added to the transfected DNA
mixture and subsequently to the medium of the cells transfected with
the GR-responsive construct GRE-TK-CAT and K14CAT. Including the
antisense DNA in the transfection mix has the advantage of ensuring
that the cells that received the transfected DNA also received the
antisense oligonucleotides. We added 5 µM concentrations of the
oligonucleotides to the medium immediately after transfection and again
18 h later. Cells were harvested 36 h after transfection, and
enzyme assays were performed.
Enzyme assays.
Briefly, the substrate solution contained 6 mg of o-nitrophenyl-D-galactoside (Sigma)
freshly dissolved in PM buffer (66 mM Na2HPO4,
33 mM NaH2PO4, 40 mM mercaptoethanol, 2 mM
MgSO4, and 0.1 mM MnCl2). The reaction mixture
contained 100 µl of substrate solution, 300 µl of PM2 buffer, and
50 µl of keratinocyte cell extract or 20 to 30 µl of HeLa cell
extract. It was incubated at 37°C until development of the yellow
color was obvious, usually for 0.5 to 1 h. The time of the
reaction was recorded, and the reaction was stopped by the addition of
0.4 ml of 1 M Na2CO3. The optical density at
420 nm was measured on a spectrophotometer (Gilford).
The CAT reaction mixture contained 69 µl of 1 M Tris HCl (pH 7.8), 1 µl of
14C-labeled chloramphenicol (Cm; 40 to 50 mCi/mmol;
New England
Nuclear), 20 µl of 4 mM acetyl-coenzyme A solution, 30 to
60 µl
of cell extract, and enough water to bring the total reaction
volume to 150 µl. After incubation at 37°C for 1 h, the
mixture
was extracted into 1 ml of ethyl acetate, phases were separated
by brief centrifugation, the organic layer was transferred to
a new
tube, and the solvent was evaporated. The residue was dissolved
in 30 µl of ethyl acetate and separated by thin-layer chromatography
on
silica gel in chloroform-methanol at 95:5. The plates were
exposed to
X-ray film for 12 to 24 h, and the intensity of the
radioactive
spots was determined using Ambis Radioanalytic System
(Ambis, Inc., San
Diego, Calif.). The conversion of chloramphenicol
to its monoacetylated
derivative was kept below 50% by varying
the amount of extract or the
duration of the
reaction.
All CAT values were normalized for transfection efficiency by
calculating the ratio of CAT activity to

-galactosidase in
each
transfected plate. Each transfection experiment was separately
performed three or more times, with each datum point resulting
from
duplicate or triplicate
transfections.
Northern blots.
Primary human keratinocytes were incubated
in the presence or absence of 1 µM DEX for 6, 12, and 24 h.
Cells were harvested by trypsinization, and the Quiagen RNeasy Kit was
used to isolate total RNA according to the manufacturer's protocol.
Then, 10 µg of total RNA was loaded per lane on the agarose gel.
Capillary transfer to the Nylon membrane (Amersham) was performed
according to a commercial protocol (Amersham). Probes K14cDNA and
HPRTcDNA were labeled using a Random Primer Labeling Kit (Boehringer
Mannheim). Next, 2 × 106 cpm of hybridization
solution (Amersham) per ml was used to hybridize the membrane according
to a commercial protocol (Amersham). The membrane was exposed to Kodak
X-ray film for 18 h at
70°C.
Electrophoretic mobility shift assays (EMSAs).
Escherichia
coli-expressed DNA-binding domain portions of hGR and cT3R were a
gift from H. H. Samuels and have been described previously
(16, 66). Oligonucleotides were synthesized on a Pharmacia
Gene Assembler Plus Synthesizer. The sequence of oligonucleotides contained a 5'-GGG overhang designed for labeling. All double-stranded oligonucleotides used were gel purified before use. The
oligonucleotides used in the EMSAs as probes were GRE
(5'-GGGAGAACATAATGTTCT), NGRE (5'-GGGGATCCGGAAGGTCACGTCCAGGATC),
K14RE (5'-GGGGCTAGCCTGTGGGTGATGAAAGCCAAGGGGAATGGAAAG), K17RE
(5'-GG GTGGGAGCTGGCAGGTGGCCAGTGGTGATGAAAGCCCAAGGG), K5RE (5'-GGGTGACCGGTGAGCTCACAGCTGCCCCCCAGGCATGCCCA), K17S1
(5'-GGGGAAAC), K17S4 (5'-GGGTGGTGA), and GRE1/2
(5'-GGGAGAACA).
Double-stranded oligonucleotides corresponding to the sequences above
were labeled with [

-
32P]dCTP, using the Klenow
fragment of
E. coli DNA polymerase I.
A total of 30,000 cpm
of the resulting probe was mixed with 0.35
pg of purified receptor
proteins and incubated first for 30 min
at room temperature and then
for 10 min at 4°C. In the experiments
with the dose curve of GR-DBD
10, 15, 20, and 30 pg of purified
protein was used. Experiments with
full-size human GR were done
similarly using recombinant GR from
Affinity Bioreagents and following
their commercial protocol. We used a
monoclonal antibody raised
against the DBD region of GR (Affinity
Bioreagents). The incubation
was done in a 30-µl volume in 25 mM Tris
(pH 7.8), 500 µM EDTA,
88 mM KCl, 10 mM 2-

-mercaptoethanol, 0.1 µg of aprotinin, 0.1
µg of poly(dI-dC), 0.05% (vol/vol) Triton
X-100, and 10% (vol/vol)
glycerol. Samples were loaded on a 4%
polyacrylamide gel and separated
by electrophoresis (20 to 25 mA) at
4°C for 2 h with a buffer
containing 10 mM Tris, 7.5 mM acetic
acid, and 40 µM EDTA (pH
7.8). Gels were dried and exposed to X-ray
film for 4 h at

70°C.
The quantification of the affinity of
protein binding to K17S1
and K17S4 was performed by spot densitometry
using the Alpha Imager
2000 Analysis System from Alpha Innotech
Corporation.
DNase I footprinting.
We have followed the general protocol
described by Lakin (31). First, 1 µg of primer K17ft
(5'-GCCCCCAGCCACCTGGGAGCT) was labeled by using
polynucleotide kinase (Promega) and [
-32P]dATP
(Amersham). Next, 1.5 × 106 cpm of each primer was
used in the primer extension reaction with K17ft
(5'-GCTTGCTCCTCTGTTTCCATTCCCCTGGGCTTTCATCACCACTGGCCACCTGCCAGCTCCCAGGTGGCTGGGGGC) as a template and Klenow endonuclease (Boehringer
Mannheim). The product was purified from a 2.5% agarose gel. The band
corresponding to the size of the probe was cut out of the gel and
eluted overnight in Tris-EDTA buffer (pH 8) at 4°C; this was followed
by ethanol precipitation. Subsequently, two different reactions were
performed in parallel: A/G Maxam-Gilbert sequencing (following the
standard protocol) (35, 36) and DNase I footprinting. For
the footprinting reaction our protocol for gel shifts was used to allow
binding of the protein to the DNA: 25 µl of the binding mix (see gel
shift protocol above) was combined with 50 ng of purified receptor
protein and 50,000 cpm of probe. After 20 min of incubation at 4°C,
50 µl of solution containing 10 mM MgCl2 and 5 mM
CaCl2 was added and incubated 1 min on ice. Next, 3 µl of
the 1:25 dilution of the DNase I (5 U/ml of stock), a dilution which we
have found to be optimal for our conditions, was added and incubated
exactly 1 min on ice. The reaction was stopped by adding 90 µl of
stop solution containing 20 mM EDTA (pH 8.0), 1% sodium dodecyl
sulfate, 0.2 M NaCl, and 100 µg of yeast RNA per ml. DNA was purified
by phenol extraction followed by ethanol precipitation. The pellet was
resuspended in 1.4 µl of 9 M urea, 1% NP-40, and, after mixing, 4.6 µl of formamide loading buffer (USB) was added. All samples were
heated at 90°C for 5 min, chilled on ice, and loaded on the 12%
sequencing polyacrylamide gel as were the samples with the A/G
Maxam-Gilbert sequencing reactions of the same DNA. Gels were subjected
to 1,000 V of current for 1 h, dried on the gel dryer, and exposed
to the X-ray film. The footprint localization was determined by the
bands that were protected by the bound protein from cleavage by DNase
I, which appeared on the film as "disappeared" bands when the
footprinted sample lane on the gel was compared with the sample that
had no protein in the mix. The protected bands were then compared with
the A/G sequence lane on the same gel, revealing the nucleotides
involved in binding of protein.
Immunohistology.
The forearms of healthy volunteers were
treated with 0.05% clobetasole propionate (Temovate) twice a day.
After 1, 2, 3, or 4 days, 4-mm punch biopsies were taken from the
treated site and from an untreated adjacent site. Biopsies were
embedded in Tissue Tek OCT compound (Miles Scientific), frozen in
liquid nitrogen, and stored at
70°C. Frozen sections of 4 to 6 µm
were cut (Fung Frigocut 2,800 E Cryostat) and then collected onto
gelatin-coated slides. The sections were stained according to a
standard immunofluorescent staining protocol (40). The
primary antibody used was polyclonal rabbit anti-human GR antibody
(Affinity Bioreagents). The secondary antibody used was anti-rabbit
fluorescein isothiocyanate preabsorbed with human serum proteins (Sigma
Immunochemicals). An Olympus Microscope was used to analyze the slides.
 |
RESULTS |
Physiology of the GRs in human keratinocytes.
We have found
that activation and nuclear translocation of GRs occur in
keratinocytes, both in vivo and in vitro, in the presence of a specific
ligand (Fig. 1 and data not shown). We
applied clobetasole propionate, a potent synthetic steroid commonly
used in dermatological therapy, topically to the skin of a volunteer.
We obtained biopsies of treated and untreated skin and stained tissue
sections with GR-specific antibody. GR, found in the cytoplasm of
untreated skin (Fig. 1A), was activated and translocated to the nuclei
in the treated skin (Fig. 1B). The activation of GR and its nuclear translocation was detected in all cell layers of the epidermis. This is
a clear demonstration of activation of a transcription factor in skin
caused by a topical treatment. We have found similar results in vitro
using primary human keratinocytes and HeLa cells (data not shown).
Within 6 h of treatment, the GR was translocated to the nuclei of
the both cell types, and the GR remained nuclear during the 24-h
treatment, thus demonstrating the activation and nuclear translocation
of the GR both in vitro and in vivo.

View larger version (114K):
[in this window]
[in a new window]
|
FIG. 1.
Activation of the GR in human epidermis in vivo.
Clobetasole propionate was applied topically to the skin of a volunteer
for 4 days. Biopsies of the treated and adjacent untreated skin and
were sectioned and stained with a GR-specific antibody. (A) GR is
present in the cytoplasm of untreated epidermis. (B) Clobetasole
propionate caused translocation of the GR from the cytoplasm to the
nucleus.
|
|
Effects of GR on transcriptional regulation of keratin genes.
To determine the effect of GCs on gene transcription in epidermis, we
have measured K14 and K16 mRNA levels during treatment of
keratinocytes with DEX. Results from the Northern blot analysis are
shown in Fig. 2. Interestingly, the K14
mRNA levels significantly decreased during the 12 h of
treatment of keratinocytes by DEX and decrease even further after 24 and 48 h of treatment (Fig. 2). Retinoic acid (RA) also
decreases K14 mRNA levels, as shown previously (Fig. 2 and
reference 59). In contrast, HPRT mRNA, which was
used as a control, was not significantly changed during the treatments.
Similar results are obtained with K16 mRNA (data not shown). Taken
together, the strong decrease of keratin mRNA levels by DEX
indicates either the inhibition of keratin gene transcription or,
alternatively, an increase in keratin mRNA turnover.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
GCs inhibit the transcription of the endogenous K14
keratin gene. The levels of K14 mRNA were measured by using
Northern blot analysis during keratinocyte treatment with DEX. The K14
mRNA levels significantly decreased during the 12-h treatment and
decreased further during 24- and 48-h treatments. RA also decreases K14
mRNA levels, as shown previously (59). In contrast,
HPRT mRNA, which was used as a control, was not significantly
changed during the treatments.
|
|
To determine if DEX inhibits keratin gene expression at the level of
transcription, we tested 10 different keratin gene promoters.
We
cotransfected keratin gene promoter-CAT constructs into keratinocytes
and HeLa cells and incubated the transfected cells in the presence
or
absence of DEX. We found that DEX suppressed the expression
of the
basal layer, as well as the disease-specific keratins K5,
K14, K6, K16,
and K17, three- to fivefold (Fig.
3). In
contrast,
the expression of the differentiation-specific keratins, K10
and
K3, and the simple epithelium-specific keratins, K8, K18, and
K19,
was not affected by DEX (Fig.
3). The expression of all 10
of these
keratins is regulated by retinoids and thyroid hormones
(
51,
62,
66).

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 3.
GCs suppress transcription of five epidermal keratin
genes. Primary human keratinocytes were cotransfected with keratin
promoter-CAT constructs, and the cells were incubated in the absence or
presence of DEX. DEX suppresses the expression of the
basal-cell-specific keratins K5 and K14 and the disease-associated
keratins K6, K16, and K17. It does not regulate the expression of the
differentiation-specific keratins K3 and K10 or the simple
epithelium-specific keratins K8, K18, and K19. GRE-CAT, a positive
control, was induced by DEX as expected. The error bars represent the
standard errors of the mean of multiple experiments, each performed
with duplicate transfections.
|
|
We used GRE-CAT, the TK promoter that contains a positive GRE, as a
control in our experiments and found it to be induced
12- to 15-fold by
DEX (Fig.
3). We have found similar results
in HeLa cells, i.e., GR
suppressed K5, K6, K14, and K17, whereas
it induces GP-CAT (data not
shown). In addition, we have cotransfected
a GR-expressing plasmid and
found that the inhibition by DEX was
not enhanced by the addition of
exogenous GR, which means that
the endogenous GR is sufficient to
regulate fully the keratin
gene expression (data not
shown).
Identification of the GREs in keratin genes.
We have
previously identified the RA and thyroid hormone response elements
(RARE and TRE) in keratin promoters and found that they are complex
sequences consisting of multiple binding sites. We hypothesized that if
the RAR and T3R bind to the complex elements, the GR may recognize and
bind the same sites. Therefore, we used these sequences as probes to
test the binding of GR. We have used K17, K5, and K14 nGREs and
recombinant GRs containing the DNA-binding domain (GR-DBD) in gel shift
experiments and found that the sequences bind GRs in addition to T3R
and RAR (Fig. 4). As controls in binding experiments we used the nGRE identified in the POMC gene that binds the
monomer-plus-dimer of GR (10) and the consensus GRE spaced
by three nucleotides (GRE-3). Both controls bound the GR as
expected, i.e., the POMC nGRE bound monomer-plus-dimer of GR, whereas the GRE-3 bound a homodimer of GR.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
GR binds to keratin GREs. EMSAs were performed with
purified GR-DBD and K5, K17, and K14 response elements as DNA probes.
The negative GRE characterized in the POMC gene (N-GRE) and the
consensus GRE spaced by three nucleotides (GRE-3) were used as control
DNA probes. As expected, GR binds to N-GRE in a monomer-plus-dimer
formation and to GRE-3 as a homodimer. GR also binds to all three
keratin GREs. GR-DBD X1, X2, and X3 refer to one, two, or three
molecules of GR-DBD bound to DNA, respectively.
|
|
Are the keratin nGREs true negative elements or does the promoter
context make keratin GREs negative? For example, the protein-protein
interaction between the receptor and an adjacent protein may cause
negative regulation. To test this possibility, we removed the
keratin
K17 nGRE from its promoter and cloned it into the TK promoter.
The
keratin GRE (KRE) cloned into TK promoter mediated repression
by GR
(Fig.
5). This means that KREs are
"self-contained negative
REs," i.e., they contain all of the
information necessary to instruct
the receptor to repress,
independently of the background and the
context of the promoter. This
result is very important because
it proves that KREs are not promoter
context dependent.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Keratin nGRE does not depend on the promoter context.
nGRE from K17 promoter was cloned into the minimal TK promoter and
tested for regulation by DEX in keratinocytes. The nGRE mediates the
suppression of the TK promoter by DEX. The positive control plasmid
GRE-TK, containing consensus GRE, similarly cloned into the TK
promoter, was activated by DEX, whereas the minimal TK promoter lacking
a response element was not regulated.
|
|
To map precisely the interactive sites between keratin GRE and GR, we
have used K17GRE in DNase I footprint experiments (Fig.
6). Interestingly, GR-DBD
binds initially to a single monomer
binding site at positions

146 to

140. As the protein concentration
increases, the GR-DBD
footprint "grows" to occupy a total of four
binding sites. In this
respect GR is quite different from T3R.
T3R binds to the same region as
GR in the K17 promoter (Fig.
6A).
The T3R footprint is adjacent to the
initial GR binding site,
and it does not grow when the protein
concentration increases.
The footprinting experiments identified nGREs
in keratin promoters
as follows: in the K5 promoter at

213 to

183,
in K6 at

132
to

98, in K14 at

79 to

49, in K16 at

162 to

127, and in K17
at

172 to

142 (Fig.
6B). Importantly, we have
found that the
sequences responsible for GR binding in the acidic
keratin promoters
have >90% identity, constituting a signature
sequence. In addition,
the GREs in the two basic keratin genes also
have a high degree
of similarity. However, the acidic signature
sequence is different
from the basic signature sequence, although both
consist of a
cluster of binding sites that bind four monomers of GR.


View larger version (4425K):
[in this window]
[in a new window]
|
FIG. 6.
Identification and mapping of keratin GREs. (A)
Footprinting analysis. Footprints of GR and T3R on K17RE are shown.
Gray rectangles represent the binding of the T3R. The black rectangle
on the left represents the initial GR binding site in the K17GRE;
increased amounts of GR cause an enlargement of the initial footprint
marked by a black rectangle on the right. (B) Signature sequences of
the keratin GREs. Keratin GREs, mapped by footprinting, have a high
degree of sequence homology specific for acidic or basic keratin genes.
The acidic signature sequences (top) and basic signature sequences
(bottom) are shown, with differences underlined and triangles marking
the insertions. The positions of the sequences in the promoter are
indicated. Respective binding sites are shown on the top marked with
roman numerals. The GRE consensus sequence is shown on the top for
comparison. (C) Identification of the GREs in keratin promoters by
site-specific mutagenesis. GREs in K5, K14, and K17 promoters were
altered to create K5M1, K14M1, and K17M1, respectively, and tested for
regulation by DEX in keratinocytes. Regulation by DEX in all three
mutant promoters was abolished, thus confirming that the GREs
identified by EMSA and footprinting mediate the regulation of keratin
gene transcription by GR.
|
|
The identified nGREs in keratin promoters provide binding to the GR,
but it is not clear that those binding sites function
as nGREs, i.e.,
cause the suppression of transcription by GR.
Therefore, we mutagenized
the sequences of nGREs in the context
of their promoters and used the
mutants in cotransfection experiments.
Introduced mutations altered
only the sequences of the binding
sites, whereas the number of the base
pairs within each binding
site remained unchanged (
51). We
have found that in all three
promoters the introduced mutations, K5M1,
K14M1, and K17M1, are
sufficient to abolish regulation by DEX (Fig.
6C). Therefore,
the identified nGREs are responsible for the regulation
of keratin
gene expression by
GR.
Four monomers of GR bind to keratin nGREs.
Intrigued by the
growth of the footprint (Fig. 6), we examined carefully the interaction
between the GR and the nGRE. The results from the gel shift assay
confirmed the footprinting results (Fig.
7). The binding assay with small amounts
of the purified GR-DBD initially revealed a binding pattern that is
consistent with the interpretation of binding of a GR monomer (Fig. 7B;
see also the Discussion). As the concentration of the receptor
increases, the monomer is converted into a two-monomer unit, which
further becomes three and finally four. These experiments suggested
that the GR binds the keratin GREs as a monomer rather than as a
homodimer. In addition, as the receptor concentration increases, the GR
binds as multiple monomers (see details in Discussion). Most
importantly, we have obtained the same binding pattern with the
full-size GR (Fig. 7B). Just like the GR-DBD, the full-size GR also
binds the keratin GRE as four monomers. The binding is specific because an antibody against the DBD of the GR blocks it. The fact that keratin
GREs bind four monomers of the GR, but not homodimers, implies a new
mechanism of negative regulation through which GR suppresses keratin
gene expression.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
Four monomers of GR bind to the keratin GREs and mediate
their suppression. (A) Summary of the sequence analysis. Introduced
mutations used in cotransfection experiments are shown as K17M1 and
K17M4. K17S4 and K17S1 probes for the gel shift experiment are shown
below with 5' GGG overhang designed for labeling. (B) Gel shift
experiment with recombinant GR-DBD (left), full-size GR (right), and a
K17RE probe is shown. GR-DBD binds initially as a monomer. As the
concentration of the GR-DBD increases, two monomers, then three, and
finally four are bound to the GREs. A gel shift experiment with
recombinant human full-size GR and a K17RE probe shows a similar
binding pattern. A monoclonal GR-specific antibody raised against the
DBD region blocks the binding. (C) The primary and quaternary binding
sites in the K17GRE have different affinities of binding to GR. GR
binds with similar affinities to the consensus GRE half-site (GRE1/2)
and the primary binding site in K17GRE (K17S1), whereas the quaternary
site (K17S4) binds with a significantly lower affinity in gel shift
experiments. (D) Binding of the GR to four binding sites in keratin GRE
is not cooperative. Mutation in the primary binding site K17M1 did not
affect the binding of the GR to the remaining three binding sites in
keratin K17GRE in the gel shift experiments. (E) The binding of all
four monomers is required for the suppression of keratin gene
transcription. Mutations introduced into the primary (K17M1) or the
quaternary (K17M4) binding sites abolished regulation by DEX in
cotransfection experiments.
|
|
What is the role of the four binding sites in keratin nGREs? To
characterize the binding sites within the keratin nGREs, we
have used
primary and quaternary binding sites as separate probes
in the gel
shift experiments. Our results show that the primary
binding site has
an approximately 10-fold-higher affinity of binding
to the GR than the
quaternary site (Fig.
7C).
One can speculate further that the binding of GR to nGRE is
cooperative, i.e., binding of the first monomer to the high-affinity
primary site initiates the binding of the remaining three monomers
to
the further sites. To test this we have mutagenized the primary
binding
site and used the mutagenized GRE as a probe in the gel
shift and
footprinting experiments. We found that the binding
of the GR to the
primary site was abolished, but the binding to
the remaining sites was
intact (Fig.
7D). Thus, the binding is
not cooperative. Finally, we
asked whether all four binding sites
are necessary for regulation.
Therefore, we have mutagenized the
primary and, separately, the
quaternary binding site in the K17
promoter, creating two mutant
promoters: K17GREM1 and K17GREM4
(for the position of the mutations,
see Fig.
7A). Neither mutant
promoter was regulated by the GR in
cotransfection experiments
(Fig.
7E), which means that all four sites
are necessary for regulation.
To test the binding of the GR to the
mutants, we used them as
probes in footprinting experiments, which show
that in both mutants
the GR binding was altered in the mutagenized
regions (data not
shown). The binding to unaltered sites was
unaffected. Taken together,
these results indicate that, although they
have different affinities
of binding to the GR, all four binding sites
are necessary for
the regulation to
occur.
Role of the coregulators in the regulation of keratin genes by
GR.
To determine whether known coregulators play a role in the
suppression of keratin gene expression by GR, we have used vectors expressing coregulators SRC-1 and GRIP-1 in cotransfection
experiments (Fig. 8). Interestingly,
SRC-1 and GRIP-1 had no effect on DEX-mediated suppression of keratin
promoters, whereas they enhanced the activation of GRE-CAT. This means
that the coregulatory proteins that enhance induction of transcription
on a consensus (positive) element are not involved in the
suppression of keratin genes by the same receptor. Since both SRC-1 and
GRIP-1 are known as coactivators, we have tested NCoR, a
corepressor, in cotransfection experiments. We have found that,
like SRC-1 and GRIP-1, NCoR had no effect on the keratin gene
regulation by DEX (Fig. 8). As expected, NCoR did not affect GRE-CAT
regulation by DEX either (Fig. 8), whereas it enhanced the repression
of TRE-CAT by unliganded T3R (data not shown). We are currently
searching for specific coregulators that interact with the GR in the
context of keratin promoters.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 8.
Role of the coregulators in regulation of keratin gene
expression by GR. We have tested coactivators SRC-1 and GRIP-1 and
corepressor NCoR in cotransfection experiments with K14CAT (top) and
GRE-CAT (bottom). None of the coregulators tested affected the
suppression of keratin gene expression by DEX. SRC-1 and GRIP-1, but
not the NCoR, enhanced the activation of the positive control, GRE-CAT,
as expected.
|
|
Role of the histone acetylation in the regulation of keratin genes
by GR.
Histone acetylase, but not histone deacetylase, plays a
role in the suppression of keratin gene expression by GR (Fig.
9). We have used antisense technology to
test the role of histone acetylation in this regulation. Using an
antisense approach one can target and block specific mRNAs, thus
inhibiting the new synthesis of a particular protein. We
added antisense oligonucleotides blocking HAT (AS-HAT)
or HDAC (AS-HDAC) in cotransfection experiments and tested their
effect on keratin gene regulation by GR. Surprisingly, we found that
AS-HAT blocks the repression of keratin gene expression by DEX, whereas
it blocks the induction of GRE-CAT (Fig. 9A). AS-HDAC had no effect on
either keratin promoters or GRE-CAT. AS-HDAC efficiently blocked the
suppression of TRE-CAT by unliganded T3R, as expected (data not shown).
To confirm that HDAC does not play a role in the suppression by DEX, we
have used TSA, a specific inhibitor of HDAC (41, 74). We
found that TSA did not affect the suppression of K14CAT by DEX, while
it did block the suppression of TRE-CAT by unliganded T3R (Fig. 9B).
Due to a toxic effect on the cells, TSA decreased the basic activity of
the reporter constructs. However, the fold regulation did not change in
the presence of DEX, thus confirming that HDAC does not play a role in
regulation of keratin gene expression by DEX. In addition, we have used
a plasmid expressing CBP in cotransfection experiments to confirm our
findings with HAT. CBP, as a component of a coactivator pathway on
positive response elements, has acetylase activity and binds to the
receptor-coregulator complex that further interacts with HAT.
Therefore, if HAT is a component of the repressor complex in the
regulation of keratin genes by GR (as our data indicate), CBP should be
a component as well. We expected that it would enhance the suppression
by DEX. Indeed, we have found that CBP does enhance suppression of
keratin gene suppression by DEX three- to fivefold (Fig. 9C). The
enhancement is concentration dependent. Conversely, CBP enhances the
DEX-mediated activation of the positive control GRE-CAT. Taken
together, this means that histone acetylation is involved in the
repression of keratin gene expression by GR. It appears that both CBP
and HAT are auxiliary proteins specific for the liganded receptor and
not direct inducers of transcription. Furthermore, our results indicate
that although HAT activity is usually associated with gene activation,
it may also participate in gene repression.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 9.
HAT, but not HDAC, is involved in the suppression of
keratin gene expression by DEX. (A) We added antisense
oligonucleotide-blocking HAT (AS-HAT) and one blocking HDAC (AS-HDAC)
into cotransfection experiments. AS-HAT blocked the repression of
keratin gene expression by DEX, whereas it blocked the induction of
GRE-CAT. AS-HDAC had no effect on either the keratin promoters or
GRE-CAT. (B) TSA, an HDAC inhibitor, does not affect the suppression of
keratin gene expression by DEX. As expected, TSA blocks the inhibition
of the positive control, thyroid response element TRE-CAT, by
unliganded T3R. (C) CBP enhances suppression of keratin gene expression
by DEX in a dose-dependent manner, whereas it enhances activation of
GRE-CAT. Three different amounts of CBP-expressing plasmid were used
(1, 3, and 9 µg).
|
|
Second mechanism of inhibition of keratin gene expression by
GR.
GR has been shown to interfere with AP1 in several systems
(3, 20, 38, 48, 68). We have shown previously that K5, K6,
K16, and K17 keratin genes contain functional AP1 sites (34, 37,
43). Therefore, we have tested the GR effect on keratin gene
regulation by AP1 protein complex. We cotransfected HeLa cells with
components of AP1, Fos, and Jun expressing plasmids along with K5 and
K17 CAT constructs and incubated the cells in the presence or absence
of DEX. We found that DEX significantly blocks the induction of K5 and
K17 by AP1 (Fig. 10). Furthermore, when
we used mutants of K5M1 and K17M1, which are not directly regulated by
DEX (see Fig. 6C), we found that both mutant promoters were induced by
AP1 and that this induction can be inhibited by DEX (Fig. 10). This
means that GCs, in addition to the direct mechanism, use another,
indirect mechanism of regulating keratin gene expression, namely, by
inhibiting their induction by AP1.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 10.
GR blocks the induction of keratin gene expression by
AP1. We have cotransfected HeLa cells with Fos and Jun expression
plasmids along with K5 and K17 CAT constructs. The transfected cells
were cultures in the presence or absence of DEX. DEX significantly
blocked the induction of K5 and K17 by the cotransfected Fos and Jun.
Furthermore, K5M1 and K17M1, which are no longer directly regulated by
DEX (see Fig. 6C), were induced by AP1, and this induction was
inhibited by DEX. The inhibition of the AP1 is mediated by a different
mechanism that does not depend on GREs in keratin promoters.
|
|
 |
DISCUSSION |
The mechanism of suppression of keratin gene transcription by GR,
described here, is an excellent example of tissue specificity in gene
regulation. There are several levels of specificity evident in this
particular mechanism. The first is the DNA sequence of the nGRE in
keratin genes. Keratin GREs constitute the first group of native
negative regulatory elements identified in a gene family. The signature
sequences are only found in the five keratin genes regulated by GR,
RAR, and T3R and not in the genes regulated only by RAR and T3R. This
suggests that the structure of the response elements in these five
keratin genes is customized to suit the purpose of binding all three
receptors. The second level is the binding of four monomers of GR,
arguably the most surprising result in this study. The unique property
of the keratin nGRE is to allow binding of four GR monomers, and only
if all four are bound does the regulation by GR occur. The third level
relates to the coregulatory proteins. The simplest explanation for
their failure to affect keratin gene regulation is that the GR is in a
monomeric form. The coregulators tested either do not bind the
monomeric GR or cannot fulfill the function if bound to the monomer. It
is also possible that suppression by the liganded receptor requires
its own set of coregulators that are yet to be discovered. The final level is the histone acetylation, which was another surprise. Our
results indicate that histone acetylase, but not histone deacetylase, plays a role in the suppression of transcription. Taken together, every
step in the path of the suppression of keratin gene expression by GR is
different than those previously described. We believe that this
mechanism is specifically designed for the purpose of targeting keratin
genes within the target tissue, i.e., epidermis.
We identified the acidic keratin signature sequence, which was 93%
identical, in the K14, K16, and K17 promoters, and the basic signature
sequence, which was 91% identical, in the K5 and K6 promoters. The
acidic and basic signature sequences do not have significant homology.
Interestingly, the GR binds to both signature sequences in identical
patterns, i.e., as four monomers, which means that, although
differentially expressed, K5, K6, K14, K16, and K17 are regulated by GR
through the same mechanism. Our results also emphasize the important
role that the DNA sequence plays in transcriptional regulation by
nuclear receptors. In this mechanism, the structure and sequence of the
nGRE in keratin promoters positions the receptor in a specific
configuration. We believe that the character of keratin nGRE is the
initial signal for suppression.
Negative regulation, or suppression, by GR and other nuclear receptors
may occur through several different mechanisms, such as direct binding
of the receptor to a negative GRE, e.g., in the keratin genes and the
POMC gene (10); direct interference with transcriptional
machinery, e.g., in the osteocalcin gene where GRE overlaps with the
TATA box (60); protein-protein interactions with positive
regulators, e.g., AP1, forming an inactive complex (20, 38,
48); and induction of expression of an inhibitor of
transcription, e.g., I
B, through which GR functionally inhibits those genes induced by NF-
B (9, 19). The molecular
mechanism of keratin gene suppression by GR described here is one of
the rare examples of active repression. Direct negative regulation proceeds through binding of the four GR monomers to the keratin GREs.
There are three lines of evidence leading to this conclusion. The first
arises from the gel shift and footprinting experiments. Judging by the
intensity of the bands and binding patterns it is clear that binding
occurs by the addition of monomers one by one, not by two dimers or a
dimer and a monomer. In addition, when one site is mutagenized the
remaining three sites bind three monomers (see Fig. 7D), thus
confirming the independent binding of monomers. The second line of
evidence arises from the mutagenesis experiments of the GR binding
sites in the keratin nGRE. Regulation occurs only if all four binding
sites are intact, although their affinities of binding are different.
The third line of evidence arises from the structure and sequence of
the binding sites. Judging by the crystal structure of the GR-DBD it is
not possible to fit the receptor dimer in any two combinations of the
GR binding sites in keratin nGRE (32, 33). According to the
current knowledge, the spacing between the half sites has to be either
three or four nucleotides, in the inverted palindrome orientation. In
addition, the sequence of the consensus binding site seems to be
restrictive, i.e., if it is changed from AGAACA to
AGGACA, it changes the affinity of binding from a
preferentially GR binding site to an ER binding site (53,
54). None of these rules, however, applies to the identified
keratin binding sites. Instead, their structure, sequence, and
orientation preclude the binding of GR homodimers. Consistently, no
homology between nGREs in keratin genes and consensus, positive, GRE
can be found. Therefore, multiple monomer binding of the GR is a novel
mechanism of suppression by glucocorticoids, so far found only in the
epidermal keratin genes.
The role of coregulators in this mechanism, although not defined, is
evidently different than what has been described in the literature. The
known general coactivators that interact with liganded GR and enhance
positive regulation do not affect the function of the same receptor
when it suppresses keratin gene expression. The most probable
explanation is that known coregulators do not functionally interact
with GR on keratin nGREs because they cannot function with monomers of
GR. There is some evidence suggesting that coregulators may interact
with two receptors at the same time through different regions and that
their function depends on the position and alosteric conformation of
the interactive sites (72). Several tissue-specific
coregulators have been described recently (50, 75), raising
the possibility that the coregulators involved in keratin regulatory
mechanism might be epidermis specific rather than general. We are
currently investigating these possibilities.
Coactivators recognize and bind to liganded receptor on one side and to
CBP/p300 on another. CBP/p300, in addition to being a histone acetylase
itself, can also interact with HAT, causing histone acetylation and
further induction of transcription. Liganded GR suppresses keratin gene
transcription, which immediately raises the question regarding the role
of histone acetylation in this regulation. One can expect that the GR
on keratin nGREs interacts somehow with other proteins that interact
with histone deacetylase (HDAC) causing repression of transcription.
Interestingly, and much to our surprise, the results show exactly the
opposite: histone acetylase, rather than deacetylase, participates in
the suppression of keratin gene transcription. This result is further
supported by our finding that CBP as well enhances the suppression of
keratin gene expression by GR. These findings are in contrast to the
previously established paradigm of HAT as a member of the
transcriptional activator complex (39). Our results suggest
that HAT is a coregulator specific for the liganded receptor and is not
directly responsible for induction of transcription. This leaves open
the question of the function of the acetylation of histones per se in
the regulation of transcription. It has been shown that CBP/p300 can
have a repressive function as well (71). Understandably, our
findings raise more questions that are subject of further studies.
However, it is clear that these findings point toward multiple
functions of histone acetylase in transcriptional regulation dependent
on a particular mechanism rather than as a general phenomenon.
Our laboratory and others have previously shown that RA and T3
receptors regulate the expression of keratin genes (62, 66). Our finding is that GCs target for regulation only those keratin genes
that are aberrantly expressed in diseased epidermis, specifically the
basal-cell-specific K5-K14, the activated keratinocyte-specific K6-K16,
and the "inflammation"-specific keratin K17. GCs do not affect
simple or differentiation-specific keratin genes. The question one must
ask is, what is the biological relevance of this regulation? Long-term
topical treatment by GCs causes thinning of epidermis (58),
which correlates with the suppression of K5-K14 keratin genes, markers
of the basal keratinocytes. In addition, GCs are known to inhibit the
wound healing process, which is attributed to their growth-inhibitory
effect (70). This correlates with the suppression of K6-K16
keratin genes, markers of activated keratinocytes (27).
Finally, GCs are most often used therapeutically for their
anti-inflammatory effects. This correlates with the suppression of
expression of the K17 keratin gene, which is present in epidermis only
during IFN-
-related inflammatory processes (26).
We have found that in addition to this direct regulation, the GR
indirectly regulates expression of keratin genes by blocking AP1
transcription factor. This indirect regulation may be particularly important in wound healing, psoriasis, and inflammatory dermatoses, which are associated with activation of the AP1 proteins
(11-13). The direct binding of the GR to GRE in the keratin
promoter is not involved in this mechanism, because the indirect
regulatory pathway is still functional in the K5 and K17 mutant
promoters, in which the direct regulation does not occur. This means
that the direct and the indirect regulatory pathways are independent of
each other and may function at the same time (Fig.
11). Homodimerization of the GR is not
necessary for the interaction with c-Jun, and it is tempting to
speculate that monomers of GR have a dual function in keratin gene
regulation: they directly inhibit the transcription by binding in
multiple copies to keratin REs, and they bind to c-Jun blocking keratin
induction by the AP1 complex. In addition, the dominant-negative GR
used to generate transgenic mice, as described by Reichardt et al., was
impaired in homodimerization, i.e., it binds to the DNA only as a
monomer (53, 54). Interestingly, the inhibition of AP1 by
the GR in this mouse was intact, and the animal did not have an
aberrant skin phenotype, suggesting that the two mechanisms of
regulation of keratin gene expression in epidermis of this mouse are
intact.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 11.
Diagram of the two different regulatory pathways of
suppression of keratin gene expression by monomers of GR.
|
|
Having potent and general transcription factors, such as nuclear
receptors, is the nature-designed distinct way of reaching specific
targets, thus differentially orchestrating gene expression in different
tissues at the same time. We describe here a novel mechanism of
suppression of transcription by GR that represents an example of
customizing a device for the transcriptional regulation to target a
specific group of genes in the target tissue, the epidermis.
 |
ACKNOWLEDGMENTS |
Our research was supported by National Institutes of Health
grants AR30682, AR39176, and AR40522. M.T.-C. is a recipient of Advanced Polymer Systems Research Fellowship Award granted through the
Dermatology Foundation and Rudolf Baer Foundation Research Grant.
We give special thanks to Irwin M. Freedberg for his support,
enthusiasm, and dedication to this project and our work. We also give
special thanks to Anita Orlin for her help, understanding, and support.
We thank R. Oshima, J. Schweizer, P. Chambon, H. H. Samuels,
B. W. O'Malley, M. Stullcup, R. H. Goodman, C. K. Glass, and L. Freedman for gifts of plasmids. We also thank E. Hadzic
and H. H. Samuels for sharing with us their expertise in nuclear
receptor purification; Laxmi Rao for her help in developing footprinting technique; and Sasa Radoja for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Ronald O. Perelman Department of Dermatology, New York University School of
Medicine, 550 First Ave., TH 361, New York, NY 10016. Phone: (212)
263-5931. Fax: (212) 263-8752. E-mail:
tomicm01{at}med.nyu.edu.
 |
REFERENCES |
| 1.
|
Abraham, L. J.,
A. D. Bradshaw,
W. Northemann, and G. H. Fey.
1991.
Identification of a glucocorticoid response element contributing to the constitutive expression of the rat liver alpha 1-inhibitor III gene.
J. Biol. Chem.
266:18268-18275[Abstract/Free Full Text].
|
| 2.
|
Alroy, I., and L. P. Freedman.
1992.
DNA binding analysis of glucocorticoid receptor specificity mutants.
Nucleic Acids Res.
20:1045-1052[Abstract/Free Full Text].
|
| 3.
|
Barrett, T. J., and W. V. Vedeckis.
1996.
Occupancy and composition of proteins bound to the AP-1 sites in the glucocorticoid receptor and c-jun promoters after glucocorticoid treatment and in different cell types.
Recept. Signal Transduct.
6:179-193[Medline].
|
| 4.
|
Blumenberg, M.
1996.
Keratinocytes: biology and differentiation, p. 58-74.
In
K. A. Arndt, P. E. Leboit, J. K. Robinson, and B. U. Wintroub (ed.), Cutaneous medicine and surgery, vol. 1. W. B. Saunders Company, Philadelphia, Pa.
|
| 5.
|
Budunova, I. V.,
S. Carbajal,
H. Kang,
A. Viaje, and T. J. Slaga.
1997.
Altered glucocorticoid receptor expression and function during mouse skin carcinogenesis.
Mol. Carcinog.
18:177-185[CrossRef][Medline].
|
| 6.
|
Cha, H. H.,
E. J. Cram,
E. C. Wang,
A. J. Huang,
H. G. Kasler, and G. L. Firestone.
1998.
Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells.
J. Biol. Chem.
273:1998-2007[Abstract/Free Full Text].
|
| 7.
|
Chakravarti, D.,
V. J. LaMorte,
M. C. Nelson,
T. Nakajima,
I. G. Schulman,
H. Juguilon,
M. Montminy, and R. M. Evans.
1996.
Role of CBP/P300 in nuclear receptor signalling.
Nature
383:99-103[CrossRef][Medline].
|
| 8.
|
Cronstein, B. N.,
S. C. Kimmel,
R. I. Levin,
F. Martiniuk, and G. Weissmann.
1992.
Corticosteroids are transcriptional regulators of acute inflammation.
Trans. Assoc. Am. Phys.
105:25-35[Medline].
|
| 9.
|
De Bosscher, K.,
M. L. Schmitz,
W. Vanden Berghe,
S. Plaisance,
W. Fiers, and G. Haegeman.
1997.
Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation.
Proc. Natl. Acad. Sci. USA
94:13504-13509[Abstract/Free Full Text].
|
| 10.
|
Drouin, J.,
Y. L. Sun,
M. Chamberland,
Y. Gauthier,
A. De Lean,
M. Nemer, and T. J. Schmidt.
1993.
Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene.
EMBO J.
12:145-156[Medline].
|
| 11.
|
Fisher, G. J.,
S. C. Datta,
H. S. Talwar,
Z. Q. Wang,
J. Varani,
S. Kang, and J. J. Voorhees.
1996.
Molecular basis of sun-induced premature skin ageing and retinoid antagonism.
Nature
379:335-339[CrossRef][Medline].
|
| 12.
|
Fisher, G. J.,
H. S. Talwar,
J. Lin,
P. Lin,
F. McPhillips,
Z. Wang,
X. Li,
Y. Wan,
S. Kang, and J. J. Voorhees.
1998.
Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo.
J. Clin. Investig.
101:1432-1440[Medline].
|
| 13.
|
Fisher, G. J., and J. J. Voorhees.
1998.
Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo.
J. Investig. Dermatol. Symp. Proc.
3:61-68[Medline].
|
| 14.
|
Forman, B. M.,
J. Casanova,
B. M. Raaka,
J. Ghysdael, and H. H. Samuels.
1992.
Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers.
Mol. Endocrinol.
6:3429-3442.
|
| 15.
|
Freedman, L. P.
1999.
Increasing the complexity of coactivation in nuclear receptor signaling.
Cell
97:5-8[CrossRef][Medline].
|
| 16.
|
Freedman, L. P.,
B. F. Luisi,
Z. R. Korszun,
R. Basavappa,
P. B. Sigler, and K. R. Yamamoto.
1988.
The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain.
Nature
334:543-546[CrossRef][Medline].
|
| 17.
|
Fuchs, E.
1990.
Epidermal differentiation: the bare essentials.
J. Cell Biol.
111:2807-2814[Free Full Text].
|
| 18.
|
Govindan, M. V.,
M. Devic,
S. Green,
H. Gronemeyer, and P. Chambon.
1985.
Cloning of the human glucocorticoid receptor cDNA.
Nucleic Acids Res.
13:8293-8304[Abstract/Free Full Text].
|
| 19.
|
Heck, S.,
K. Bender,
M. Kullmann,
M. Gottlicher,
P. Herrlich, and A. C. Cato.
1997.
I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor.
EMBO J.
16:4698-4707[CrossRef][Medline].
|
| 20.
|
Heck, S.,
M. Kullmann,
A. Gast,
H. Ponta,
H. J. Rahmsdorf,
P. Herrlich, and A. C. Cato.
1994.
A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1.
EMBO J.
13:4087-4095[Medline].
|
| 21.
|
Heinzel, T.,
R. M. Lavinsky,
T. M. Mullen,
M. Söderstrom,
C. D. Laherty,
J. Torchia,
W. M. Yang,
G. Brard,
S. D. Ngo,
J. R. Davie,
E. Seto,
R. N. Eisenman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1997.
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.
Nature
387:6628-6638.
|
| 22.
|
Hong, H.,
K. Kohli,
M. J. Garabedian, and M. R. Stallcup.
1997.
GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors.
Mol. Cell. Biol.
17:2735-2744[Abstract].
|
| 23.
|
Hong, H.,
K. Kohli,
A. Trivedi,
D. L. Johnson, and M. R. Stallcup.
1996.
GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors.
Proc. Natl. Acad. Sci. USA
93:4948-4952[Abstract/Free Full Text].
|
| 24.
|
Horwitz, K. B.,
T. A. Jackson,
D. L. Bain,
J. K. Richer,
G. S. Takimoto, and L. Tung.
1996.
Nuclear receptor coactivators and corepressors.
Mol. Endocrinol.
10:1167-1177[Abstract/Free Full Text].
|
| 25.
|
Jiang, C. K.,
D. Connolly, and M. Blumenberg.
1991.
Comparison of methods for transfection of human epidermal keratinocytes.
J. Investig. Dermatol.
97:969-973[CrossRef][Medline].
|
| 26.
|
Jiang, C. K.,
S. Flanagan,
M. Ohtsuki,
K. Shuai,
I. M. Freedberg, and M. Blumenberg.
1994.
Disease-activated transcription factor: allergic reactions in human skin cause nuclear translocation of STAT-91 and induce synthesis of keratin K17.
Mol. Cell. Biol.
14:4759-4769[Abstract/Free Full Text].
|
| 27.
|
Jiang, C. K.,
T. Magnaldo,
M. Ohtsuki,
I. M. Freedberg,
F. Bernerd, and M. Blumenberg.
1993.
Epidermal growth factor and transforming growth factor alpha specifically induce the activation- and hyperproliferation-associated keratins 6 and 16.
Proc. Natl. Acad. Sci. USA
90:6786-6790[Abstract/Free Full Text].
|
| 28.
|
Kamei, Y.,
L. Xu,
T. Heinzel,
J. Torchia,
R. Kurokawa,
B. Gloss,
S. C. Lin,
R. A. Heyman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1996.
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.
Cell
85:403-414[CrossRef][Medline].
|
| 29.
|
Kupper, T.
1990.
The role of cells and cytokines in immunity and inflammation, p. 285-305.
In
J. Oppenheim, and E. Shevach (ed.), Immunophysiology. Oxford University Press, New York, N.Y.
|
| 30.
|
Kwok, R. P.,
J. R. Lundblad,
J. C. Chrivia,
J. P. Richards,
H. P. Bächinger,
R. G. Brennan,
S. G. Roberts,
M. R. Green, and R. H. Goodman.
1994.
Nuclear protein CBP is a coactivator for the transcription factor CREB.
Nature
370:223-226[CrossRef][Medline].
|
| 31.
|
Lakin, N. D.
1993.
Determination of DNA sequences that bind transcription factors by DNA footprinting, p. 27-46.
In
D. S. Latchman (ed.), Transcription factors: a practical approach. IRL Press at Oxford University Press, New York, N.Y.
|
| 32.
|
Luisi, B. F.,
J. W. Schwabe, and L. P. Freedman.
1994.
The steroid/nuclear receptors: from three-dimensional structure to complex function.
Vitam. Horm.
49:1-47[Medline].
|
| 33.
|
Luisi, B. F.,
W. X. Xu,
Z. Otwinowski,
L. P. Freedman,
K. R. Yamamoto, and P. B. Sigler.
1991.
Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA.
Nature
352:497-505[CrossRef][Medline].
|
| 34.
|
Magnaldo, T.,
F. Bernerd,
I. M. Freedberg,
M. Ohtsuki, and M. Blumenberg.
1993.
Transcriptional regulators of expression of K6 and K16, the disease-associated keratin.
DNA Cell Biol.
12:911-923[Medline].
|
| 35.
|
Maxam, A. M., and W. Gilbert.
1977.
A new method for sequencing DNA.
Proc. Natl. Acad. Sci. USA
74:560-564[Abstract/Free Full Text].
|
| 36.
|
Maxam, A. M., and W. Gilbert.
1992.
A new method for sequencing DNA.
Bio/Technology
24:99-103[Medline].
|
| 37.
|
Milisavljevic, V.,
I. M. Freedberg, and M. Blumenberg.
1996.
Characterization of nuclear protein binding sites in the promoter of keratin K17 gene.
DNA Cell Biol.
15:65-74[Medline].
|
| 38.
|
Miner, J. N., and K. R. Yamamoto.
1992.
The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element.
Genes Dev.
12B:2491-2501.
|
| 39.
|
Montminy, M.
1997.
Transcriptional activation. Something new to hang your HAT on.
Nature
387:654-655[CrossRef][Medline].
|
| 40.
|
Mutasim, D. F.,
A. Vaughan,
N. Supapannachart, and J. Farooqui.
1993.
Skin explant culture: a reliable method for detecting pemphigoid antibodies in pemphigoid sera that are negative by standard immunofluorescence and immunoblotting.
J. Investig. Dermatol.
101:624-627[CrossRef][Medline].
|
| 41.
|
Niki, T.,
K. Rombouts,
P. De Bleser,
K. De Smet,
V. Rogiers,
D. Schuppan,
M. Yoshida,
G. Gabbiani, and A. Geerts.
1999.
A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture.
Hepatology
29:858-867[CrossRef][Medline].
|
| 42.
|
Ogryzko, V. V.,
R. L. Schiltz,
V. Russanova,
B. H. Howard, and Y. Nakatani.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953-959[CrossRef][Medline].
|
| 43.
|
Ohtsuki, M.,
S. Flanagan,
I. M. Freedberg, and M. Blumenberg.
1993.
A cluster of five nuclear proteins regulates keratin gene transcription.
Gene Expr.
3:201-213[Medline].
|
| 44.
|
Oñate, S. A.,
V. Boonyaratanakornkit,
T. E. Spencer,
S. Y. Tsai,
M. J. Tsai,
D. P. Edwards, and B. W. O'Malley.
1998.
The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors.
J. Biol. Chem.
273:12101-12108[Abstract/Free Full Text].
|
| 45.
|
Oñate, S. A.,
S. Y. Tsai,
M. J. Tsai, and B. W. O'Malley.
1995.
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.
Science
270:1354-1357[Abstract/Free Full Text].
|
| 46.
|
Oshima, R. G.,
H. Baribault, and C. Caulín.
1996.
Oncogenic regulation and function of keratins 8 and 18.
Cancer Metastasis Rev.
15:445-471[CrossRef][Medline].
|
| 47.
|
Pazin, M. J., and J. T. Kadonaga.
1997.
What's up and down with histone deacetylation and transcription?
Cell
89:325-328[CrossRef][Medline].
|
| 48.
|
Pearce, D.,
W. Matsui,
J. N. Miner, and K. R. Yamamoto.
1998.
Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites.
J. Biol. Chem.
273:30081-30085[Abstract/Free Full Text].
|
| 49.
|
Pratt, W. B.
1993.
The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor.
J. Biol. Chem.
268:21455-21458[Free Full Text].
|
| 50.
|
Puigserver, P.,
Z. Wu,
C. W. Park,
R. Graves,
M. Wright, and B. M. Spiegelman.
1998.
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis.
Cell
92:829-839[CrossRef][Medline].
|
| 51.
|
Radoja, N.,
D. V. Diaz,
T. J. Minars,
I. M. Freedberg,
M. Blumenberg, and M. Tomic-Canic.
1997.
Specific organization of the negative response elements for retinoic acid and thyroid hormone receptors in keratin gene family.
J. Investig. Dermatol.
109:566-572[CrossRef][Medline].
|
| 52.
|
Randolph, R. K., and M. Simon.
1993.
Characterization of retinol metabolism in cultured human epidermal keratinocytes.
J. Biol. Chem.
268:9198-9205[Abstract/Free Full Text].
|
| 53.
|
Reichardt, H. M.,
K. H. Kaestner,
J. Tuckermann,
O. Kretz,
O. Wessely,
R. Bock,
P. Gass,
W. Schmid,
P. Herrlich,
P. Angel, and G. Schutz.
1998.
DNA binding of the glucocorticoid receptor is not essential for survival.
Cell
93:531-541[CrossRef][Medline].
|
| 54.
|
Reichardt, H. M.,
K. H. Kaestner,
O. Wessely,
P. Gass,
W. Schmid, and G. Schutz.
1998.
Analysis of glucocorticoid signalling by gene targeting.
J. Steroid Biochem. Mol. Biol.
65:111-115[CrossRef][Medline].
|
| 55.
|
Scheinman, R. I.,
A. Gualberto,
C. M. Jewell,
J. A. Cidlowski, and A. S. Baldwin, Jr.
1995.
Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.
Mol. Cell. Biol.
15:943-953[Abstract].
|
| 56.
|
Shibata, H.,
T. E. Spencer,
S. A. Onate,
G. Jenster,
S. Y. Tsai,
M. J. Tsai, and B. W. O'Malley.
1997.
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
Recent Prog. Horm. Res.
52:141-164.
|
| 57.
|
Slater, E. P.,
H. Hesse, and M. Beato.
1994.
Regulation of transcription by steroid hormones.
Ann. N. Y. Acad. Sci.
733:103-112[Medline].
|
| 58.
|
Sloan, K. B.,
O. E. Araujo, and F. P. Flowers.
1996.
Topical corticosteroid therapy, p. 160-166.
In
K. A. Arndt, P. E. Leboit, J. K. Robinson, and B. U. Wintraub (ed.), Cutaneous medicine and surgery, vol. 1. W. B. Saunders Company, Philadelphia, Pa.
|
| 59.
|
Stellmach, V.,
A. Leask, and E. Fuchs.
1991.
Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and squamous cell carcinoma cells.
Proc. Natl. Acad. Sci. USA
88:4582-4586[Abstract/Free Full Text].
|
| 60.
|
Stromstedt, P. E.,
L. Poellinger,
J. A. Gustafsson, and J. Carlstedt-Duke.
1991.
The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation.
Mol. Cell. Biol.
11:3379-3383[Abstract/Free Full Text].
|
| 61.
|
Sutter, C.,
R. Nischt,
H. Winter, and J. Schweizer.
1991.
Aberrant in vitro expression of keratin K13 induced by Ca2+ and vitamin A acid in mouse epidermal cell lines.
Exp. Cell Res.
195:183-193[CrossRef][Medline].
|
| 62.
|
Tomic, M.,
C. K. Jiang,
H. S. Epstein,
I. M. Freedberg,
H. H. Samuels, and M. Blumenberg.
1990.
Nuclear receptors for retinoic acid and thyroid hormone regulate transcription of keratin genes.
Cell Regul.
1:965-973[Medline].
|
| 63.
|
Tomic-Canic, M.,
F. Bernerd, and M. Blumenberg.
1996.
A simple method to introduce internal deletions or mutations into any position of a target DNA sequence.
Methods Mol. Biol.
57:249-257[Medline].
|
| 64.
|
Tomic-Canic, M.,
M. Komine,
I. M. Freedberg, and M. Blumenberg.
1998.
Epidermal signal transduction and transcription factor activation in activated keratinocytes.
J. Dermatol. Sci.
17:167-181[CrossRef][Medline].
|
| 65.
|
Tomic-Canic, M.,
I. Sunjevaric,
I. M. Freedberg, and M. Blumenberg.
1992.
Identification of the retinoic acid and thyroid hormone receptor-responsive element in the human K14 keratin gene.
J. Investig. Dermatol.
99:842-847[CrossRef][Medline].
|
| 66.
|
Tomie-Canie, M.,
D. Day,
H. H. Samuels,
I. M. Freedberg, and M. Blumenberg.
1996.
Novel regulation of keratin gene expression by thyroid hormone and retinoid receptors.
J. Biol. Chem.
271:1416-1423[Abstract/Free Full Text].
|
| 67.
|
Torchia, J.,
D. W. Rose,
J. Inostroza,
Y. Kamei,
S. Westin,
C. K. Glass, and M. G. Rosenfeld.
1997.
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.
Nature
387:677-684[CrossRef][Medline].
|
| 68.
|
Uht, R. M.,
C. M. Anderson,
P. Webb, and P. J. Kushner.
1997.
Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element.
Endocrinology
138:2900-2908[Abstract/Free Full Text].
|
| 69.
|
Verreault, A.,
P. D. Kaufman,
R. Kobayashi, and B. Stillman.
1998.
Nucleosomal DNA regulates the core-histone-binding subunit of the human Hat1 acetyltransferase.
Curr. Biol.
8:96-108[CrossRef][Medline].
|
| 70.
|
Vickers, C. F. H.
1987.
Topical corticosteroids, p. 2540-2545.
In
T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Freedberg, and K. F. Austen (ed.), Dermatology in general medicine, vol. 2. McGraw-Hill, Inc., New York, N.Y.
|
| 71.
|
Waltzer, L., and M. Bienz.
1998.
Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling.
Nature
395:521-525[CrossRef][Medline].
|
| 72.
|
Westin, S.,
R. Kurokawa,
R. T. Nolte,
G. B. Wisely,
E. M. McInerney,
D. W. Rose,
M. V. Milburn,
M. G. Rosenfeld, and C. K. Glass.
1998.
Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators.
Nature
395:199-202[CrossRef][Medline].
|
| 73.
|
Wolffe, A. P.
1997.
Transcriptional control. Sinful repression.
Nature
387:16-17[CrossRef][Medline].
|
| 74.
|
Yoshida, M.,
S. Horinouchi, and T. Beppu.
1995.
Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function.
Bioessays
17:423-430[CrossRef][Medline].
|
| 75.
|
Zamir, I.,
J. Dawson,
R. M. Lavinsky,
C. K. Glass,
M. G. Rosenfeld, and M. A. Lazar.
1997.
Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex.
Proc. Natl. Acad. Sci. USA
94:14400-14405[Abstract/Free Full Text].
|
Molecular and Cellular Biology, June 2000, p. 4328-4339, Vol. 20, No. 12
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Donet, E., Bosch, P., Sanchis, A., Bayo, P., Ramirez, A., Cascallana, J. L., Bravo, A., Perez, P.
(2008). Transrepression Function of the Glucocorticoid Receptor Regulates Eyelid Development and Keratinocyte Proliferation but Is Not Sufficient to Prevent Skin Chronic Inflammation. Mol. Endocrinol.
22: 799-812
[Abstract]
[Full Text]
-
Bayo, P., Sanchis, A., Bravo, A., Cascallana, J. L., Buder, K., Tuckermann, J., Schutz, G., Perez, P.
(2008). Glucocorticoid Receptor Is Required for Skin Barrier Competence. Endocrinology
149: 1377-1388
[Abstract]
[Full Text]
-
Li, C., Li, Y., Li, Y., Liu, H., Sun, Z., Lu, J., Zhao, Y.
(2008). Glucocorticoid repression of human with-no-lysine (K) kinase-4 gene expression is mediated by the negative response elements in the promoter. J Mol Endocrinol
40: 3-12
[Abstract]
[Full Text]
-
Stojadinovic, O., Lee, B., Vouthounis, C., Vukelic, S., Pastar, I., Blumenberg, M., Brem, H., Tomic-Canic, M.
(2007). Novel Genomic Effects of Glucocorticoids in Epidermal Keratinocytes: INHIBITION OF APOPTOSIS, INTERFERON-{gamma} PATHWAY, AND WOUND HEALING ALONG WITH PROMOTION OF TERMINAL DIFFERENTIATION. J. Biol. Chem.
282: 4021-4034
[Abstract]
[Full Text]
-
Chen, Y., Nickola, T. J., DiFronzo, N. L., Colberg-Poley, A. M., Rose, M. C.
(2006). Dexamethasone-Mediated Repression of MUC5AC Gene Expression in Human Lung Epithelial Cells. Am. J. Respir. Cell Mol. Bio.
34: 338-347
[Abstract]
[Full Text]
-
Stojadinovic, O., Brem, H., Vouthounis, C., Lee, B., Fallon, J., Stallcup, M., Merchant, A., Galiano, R. D., Tomic-Canic, M.
(2005). Molecular Pathogenesis of Chronic Wounds: The Role of {beta}-Catenin and c-myc in the Inhibition of Epithelialization and Wound Healing. Am. J. Pathol.
167: 59-69
[Abstract]
[Full Text]
-
Varley, C. L., Stahlschmidt, J., Smith, B., Stower, M., Southgate, J.
(2004). Activation of Peroxisome Proliferator-Activated Receptor-{gamma} Reverses Squamous Metaplasia and Induces Transitional Differentiation in Normal Human Urothelial Cells. Am. J. Pathol.
164: 1789-1798
[Abstract]
[Full Text]
-
Radoja, N., Stojadinovic, O., Waseem, A., Tomic-Canic, M., Milisavljevic, V., Teebor, S., Blumenberg, M.
(2004). Thyroid Hormones and Gamma Interferon Specifically Increase K15 Keratin Gene Transcription. Mol. Cell. Biol.
24: 3168-3179
[Abstract]
[Full Text]
-
Nguyen, V. T., Arredondo, J., Chernyavsky, A. I., Kitajima, Y., Pittelkow, M., Grando, S. A.
(2004). Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes. J. Biol. Chem.
279: 2135-2146
[Abstract]
[Full Text]
-
De Bosscher, K., Vanden Berghe, W., Haegeman, G.
(2003). The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression. Endocr. Rev.
24: 488-522
[Abstract]
[Full Text]
-
Kaufman, C. K., Sinha, S., Bolotin, D., Fan, J., Fuchs, E.
(2002). Dissection of a Complex Enhancer Element: Maintenance of Keratinocyte Specificity but Loss of Differentiation Specificity. Mol. Cell. Biol.
22: 4293-4308
[Abstract]
[Full Text]
-
Jho, S. H., Radoja, N., Im, M. J., Tomic-Canic, M.
(2001). Negative Response Elements in Keratin Genes Mediate Transcriptional Repression and the Cross-talk among Nuclear Receptors. J. Biol. Chem.
276: 45914-45920
[Abstract]
[Full Text]
-
Ou, X.-M., Storring, J. M., Kushwaha, N., Albert, P. R.
(2001). Heterodimerization of Mineralocorticoid and Glucocorticoid Receptors at a Novel Negative Response Element of the 5-HT1A Receptor Gene. J. Biol. Chem.
276: 14299-14307
[Abstract]
[Full Text]
-
Sugihara, T. M., Kudryavtseva, E. I., Kumar, V., Horridge, J. J., Andersen, B.
(2001). The POU Domain Factor Skin-1a Represses the Keratin 14 Promoter Independent of DNA Binding. A POSSIBLE ROLE FOR INTERACTIONS BETWEEN Skn-1a AND CREB-BINDING PROTEIN/p300. J. Biol. Chem.
276: 33036-33044
[Abstract]
[Full Text]
-
Collingwood, T. N., Urnov, F. D., Chatterjee, V. K. K., Wolffe, A. P.
(2001). Chromatin Remodeling by the Thyroid Hormone Receptor in Regulation of the Thyroid-stimulating Hormone alpha -Subunit Promoter. J. Biol. Chem.
276: 34227-34234
[Abstract]
[Full Text]